title: Is a decline in estimated GFR an appropriate surrogate end point for renoprotection drug trials?
authors.affiliation: Dorn Research Institute, WJBD VA Hospital, Columbia, South Carolina, USA.
authors.forename: Steven J
authors.initials: SJ
authors.lastname: Rosansky
authors.affiliation: Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA.
authors.forename: Richard J
authors.initials: RJ
authors.lastname: Glassock
mesh_terms: D015415:Biomarkers; D004358:Drug Therapy; D023381:Endpoint Determination; D005919:Glomerular Filtration Rate; D006801:Humans; D007676:Kidney Failure, Chronic / Q000517:prevention & control*; D016032:Randomized Controlled Trials as Topic
chemical_list: D015415:Biomarkers